COGNANO

COGNANO is a private Japanese biotech company developing antibody-driven and AI-enabled drug discovery and diagnostic technologies. The company builds large proprietary VHH antibody datasets from in-house alpaca and shark immunization systems, then uses its IBMET platform to identify novel antigens, biomarkers, and potential therapeutic targets upstream of conventional target-based drug discovery. Its disclosed work includes triple-negative breast cancer biomarker discovery, SARS-CoV-2 spike-binding nanobody research, IL-6-related antibody datasets, and emerging pancreatic cancer antigen programs. COGNANO positions itself as a tech-bio platform company combining wet-lab antibody generation, sequencing, and machine learning to accelerate therapeutic and diagnostic development.